First on CNN: Dangerously high levels of arsenic and cadmium found in store-bought rice, report finds
Samples of store-bought rice from more than 100 different brands purchased in the United States contained dangerously high levels of arsenic and cadmium, according to a new report shared first with CNN.
'Even at low levels, both arsenic and cadmium have been linked to serious health harms, including diabetes, developmental delays, reproductive toxicity and heart disease,' said coauthor Jane Houlihan, research director for Healthy Babies, Bright Futures. The organization, which is dedicated to reducing children's exposure to toxic chemicals, produced the report.
'Heavy metal contamination in young children is especially concerning, as early-life exposures are associated with reduced IQ and a range of cognitive and behavioral problems,' Houlihan said.
One in four samples of rice purchased from grocery and retail stores across the United States exceeded levels of inorganic arsenic set in 2021 by the US Food and Drug Administration for infant rice cereal, according to the report published Thursday.
'The FDA set a limit for inorganic arsenic in infant rice cereal of 100 parts per billion, and since then we've seen levels in those cereals drop by 45%,' Houlihan said. 'But the FDA did not address inorganic arsenic levels in the rice families purchased to cook and serve.
'Yet it turns out that for very young children, ages 0 to 2 years, rice is a more important source of inorganic arsenic than infant rice cereal,' she added. 'It's really the rice itself that's driving higher exposures.'
Arsenic is a natural element found in soil, water and air, with the inorganic form being the most toxic. 'Inorganic' is a chemical term and has nothing to do with the method of farming.
Arsenic is also a carcinogen, and early-life exposures — including during pregnancy — are especially dangerous, possibly leading to spontaneous abortion, stillbirth and preterm birth as well as later neurodevelopmental disorders, according to the American Academy of Pediatrics.
The USA Rice Federation, which represents American growers, told CNN via email that rice grown in the United States contains the lowest levels of inorganic arsenic in the world.
'While we do not agree that there is a public health safety issue as a result of trace amounts of arsenic in rice, we will continue to work with the U.S. Food and Drug Administration (FDA) to ensure the U.S. rice supply meets any threshold established,' said Michael Klein, vice president of communications and strategic development at USA Rice.
'It is worth noting (that) the top source (42%) of arsenic in the diet of Americans is fruits, vegetables, and fruit juice. Rice is 17 percent,' Klein said.
That's an unfair comparison, Houlihan said, because dozens of different fruits and vegetables contribute to that figure of 42%.
'In contrast, rice alone — one specific food — contributes 17%, likely making it the single largest individual food source of arsenic in the American diet,' she said.
A global concern
Rice is the 'most widely consumed solid food in the world,' according to the report, and a regular part of the diets of more than 1 billion children globally. In some cultures, rice is served at every meal.
'On average, for all children ages 0 to 2 years, rice accounts for 7.5% of their arsenic exposure, more than any other solid food,' Houlihan said. 'For Hispanic and Latino children of the same age, that level rises to 14%.'
However, many Latino families are not aware of the dangers of arsenic in rice, said Juan Roberto Madrid, an advocate for the environmental advocacy association GreenLatinos, which partnered on the new report.
'In fact many of our full time staff were not even aware of the dangers of arsenic in rice,' Madrid said in an email. 'Our communities must understand what arsenic does to babies and that there are alternatives available. This is not a cause for alarm, but rather a cause for concern.'
For Asian children, the levels are even higher, Houlihan said. 'For babies 0 to 2 (years), rice accounts for 30.5% of the arsenic in their diet. It's even higher for Asian children between 18 (months) and 24 months. Rice accounts for nearly 55% of their arsenic exposure.'
Some Asian families are aware of the presence of heavy metals in rice, but not the dangers posed by arsenic, said Gloria Tan, executive director of Gum Moon's women's residence at the Asian Women's Resource Center in San Francisco. Gum Moon, which stands for 'golden door,' has been providing services to Asian women since 1868 and was a partner in the new report.
'Knowing that there are dangers of arsenic might make families reconsider their rice choice,' Tan said in an email. 'I think some families may be receptive to the idea of switching to a less contaminated grain.'
Comparing rice with ancient grains
The new report analyzed the total heavy metal content in 145 samples of rice varieties grown in India, Italy, Thailand and the United States that were purchased by shoppers in the US.
'The researchers used a certified, accredited lab to measure arsenic and other heavy metals in rice samples, confirming that this is an issue with real-world implications,' said Tasha Stoiber, a senior scientist at the Environmental Working Group, via email. EWG is a consumer organization that monitors exposure to heavy metals, plastics and other dangerous chemicals. Stoiber was not involved in the new research.
The independent lab also tested another 66 samples of nine ancient grains: amaranth, barley, buckwheat, bulgur, couscous, farro, millet, quinoa and spelt.
Results showed rice purchased by shoppers contained 28 times more arsenic than the alternative grains. The group of alternative grains, however, contained 1.5 times more cadmium than rice. Still, overall levels of heavy metals were three times lower in the nine grains compared with the levels found in the purchased rice.
Like arsenic, cadmium easily crosses the placental barrier to the fetus, potentially causing neurodevelopmental harm. Cadmium is also a known carcinogen and has been connected to harm to the kidneys, bone, stomach, lungs and more.
'Most research has focused solely on arsenic, but that leaves out an important part of the rice safety story,' Houlihan said. 'By including cadmium in our analysis, we're able to give a more complete picture of how different rice types compare in terms of overall toxic metal exposure.'
Rice type and growing region matter
The type of rice and how it's grown and processed can impact levels of arsenic and other heavy metals, experts say. Brown and wild rice often contain the highest levels because the milling process used to create white rice removes the outer layers of the hull, where heavy metals are concentrated.
Lab testing found purchased samples of US-grown brown rice contained 151 parts per billion of heavy metals — 129 of that due to arsenic. Arborio rice grown in Italy, which is typically used to make risotto, and white rice grown in the Southeast US (often labeled as simply 'USA') were almost as high in total heavy metals as brown rice, the report said.
Arborio rice from Italy contained 101 parts per billion of arsenic — total heavy metal load in the purchased samples was 142 parts per billion. White rice grown in the US contained 95 parts per billion of arsenic, with a total heavy metal count of 118 parts per billion.
Basmati rice from India, jasmine rice from Thailand and California-grown sushi and Calrose rice (a form of sushi rice) were at or below the 100 parts per billion levels set by the FDA for arsenic in infant rice cereals. However, the Indian basmati and Italian Arborio varieties contained the highest average levels of cadmium.
The California-grown rice had the lowest overall heavy metal content — 65 parts per billion, with 55 parts per billion from arsenic — making it an excellent choice to reduce overall exposure, Houlihan said.
Consumers should be wary, however, of precooked rice, including instant (one-minute and five-minute rice), parboiled (10-minute rice), and ready-to-heat-and-eat packaged rice, she said.
'Studies have shown the processing used to create instant rice can create additional toxins, and the ready-to-heat products are cooked inside the plastic containers, potentially releasing toxic chemicals,' Houlihan said.
While the report does list the names of the 105 brands tested, that's not what's important when choosing rice with the lowest levels of heavy metals, she added.
'Results between brands didn't tend to vary,' Houlihan said. 'The controlling factors for avoiding heavy metal levels seems to be the rice variety and the country of origin, not the brand of rice. So make sure you know where your rice comes from.
'Unfortunately, not all brands label the source of their product, so you'll have to do some shopping to find those that do,' she added.
This lack of clear package labeling is a gap that should be addressed by industry and the federal government, EWG's Stoiber said. 'Stronger federal oversight and clearer labeling would go a long way to keep children safe from exposure to arsenic in food.'
The FDA takes the presence of heavy metals in food extremely seriously, said Andrew Nixon, director of communications for the US Department of Health and Human Services, which oversees the FDA.
'Under Secretary (Robert F.) Kennedy (Jr.)'s leadership, HHS is conducting a comprehensive review of chemicals in the food supply — both those added intentionally and those like heavy metals that are environmental contaminants,' Nixon said in an email.
Additional ways to lower exposure
There is an easy way to eliminate nearly two-thirds of the arsenic in rice — cook it like pasta. Using 6 to 10 cups of water for every cup of rice and draining the excess before eating can remove up to 60% of arsenic. However, only rinsing rice before cooking doesn't work, according to the report.
To further the amount of arsenic removed, soak rice for a half hour or overnight and drain before cooking as suggested.
Keep in mind that boiling and draining will also remove some of the fortified iron added to rice. Iron is important for proper development and many babies are often deficient, the report said, so consult a pediatrician about adding iron-rich foods. Beans, eggs, fresh fruits and vegetables, lean red meat, and poultry are good sources.
In addition, there are nutrients such as B vitamins, calcium, zinc and vitamin C that can help 'reduce the body's absorption of contaminants or speed up their excretion,' the report said. 'Find them in foods like lean meat, yogurt, cheese, leafy greens, broccoli, beans and lentils, citrus fruits, strawberries, and peppers.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
29 minutes ago
- Bloomberg
Novo Nordisk's CagriSema Shot Tied to Greater Weight Loss at Lower Doses
Novo Nordisk A/S's next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly, patients who chose to stick with a lower dose lost more weight on average. The studies allowed patients to stop at lower doses of the drug, an unusual option in a trial. Researchers presenting new data Sunday at the American Diabetes Association meeting in Chicago say the findings offer clues as to how the drug would be used in real life. There's a group of people who respond very well to this medicine, said Timothy Garvey, director of the Diabetes Research Center at the University of Alabama at Birmingham, who helped lead the trials.
Yahoo
43 minutes ago
- Yahoo
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
By Deena Beasley (Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical program is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's® (ADA) 85th Scientific Sessions and published in NEJM. "In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. "These results reinforce our confidence in CagriSema and we continue to study the potential of this combination through the REDEFINE trials." CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7]; p<0.001) if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group (estimated difference [95% CI] -17.3 [-18.1 to -16.6]; p<0.001).1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI <30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group, 10.2% reached that threshold at 68 weeks.1 Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body-weight reduction of ≥25% ([95% CI] 39.5 (37.1 to 41.9); p<0.001).* Additionally, 23.1% lost ≥30% of their body weight ([95% CI] 22.7 (20.7 to 24.7); p<0.001).1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction ([95% CI] 33.7 (31.5 to 35.9); p<0.001) and 19.3% achieved ≥30% body-weight reduction ([95% CI] 18.9 (17.1 to 20.7); p<0.001).1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus -5.7% and -4.3% for the placebo group, respectively. "In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions," said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. "Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement." Safety data generated in the REDEFINE 1 and 2 trials was comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), vomiting (26.1% vs 4.1%) and were mostly transient and mild-to-moderate in severity.1 Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM.3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was -15.7% with CagriSema versus -3.1% with placebo (estimated difference [95% CI] -12.6% [-13.4 to -11.7]; p<0.001).3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was -13.7% with CagriSema versus -3.4% with placebo (estimated difference [95% CI] -10.4% [-11.2 to -9.5]; p<0.001).3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by >5% (83.6% vs 30.8% of participants; p<0.001), ≥10% (65.6% vs 10.3%), ≥15% (43.9% vs 2.4%), and ≥20% (22.9% vs 0.5%; p<0.001).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3 The REDEFINE clinical program will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand: this estimand estimates what the effect would be if all participants adhered to treatment** Based on the treatment policy estimand: treatment effect regardless of treatment adherence About CagriSemaCagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss. About the REDEFINE clinical trial programREDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight. Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2. About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.9,10 In the US, about 40% of adults live with obesity.11 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References: Garvey T, Blüher M, Contreras C, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;10.1056/NEJMoa2502081. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: Davies M, Bajaj H, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;10.1056/NEJMoa2502082. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
